Skip to main content
Top
Published in: BMC Urology 1/2016

Open Access 01-12-2016 | Research article

Assessment of a new point-of-care system for detection of prostate specific antigen

Authors: Steffen Rausch, Joerg Hennenlotter, Josef Wiesenreiter, Andrea Hohneder, Julian Heinkele, Christian Schwentner, Arnulf Stenzl, Tilman Todenhöfer

Published in: BMC Urology | Issue 1/2016

Login to get access

Abstract

Background

Measurement of the prostate specific antigen (PSA) remains an important tool in prostate cancer (PC) diagnosis. Due to limited availability of laboratory devices in an outpatient setting, compact and easy-to-handle point-of-care (POC) systems are desirable. Recently, a chip for PSA measurement on the concile® Ω100 POC reader platform was introduced. To investigate the clinical applicability, we evaluated the system in a consecutive cohort of patients undergoing PSA measurement in our outpatient clinic.

Methods

Between 07/2014 and 01/2015, PSA was analyzed in a total of 198 patients by the POC reader system and in parallel by an Immulite 2000® and Centaur® standard laboratory system, respectively. By standard (Immulite®) measurement, 67 (34,2 %) had PSA > 4 ng/ml and 131 (65,8 %) had PSA ≤ 4 ng/ml. Results were correlated by linear regression analyses for all patients and within PSA subgroups. For patients with available prostate histology after PSA measurement (n = 68), receiver-operating characteristic curves were created and area under the curve (AUC), sensitivity and specificity for the prediction of PC at best cut-off value were calculated.

Results

The coefficients of determination (r2) for the POC device compared to laboratory testing were 0.72 (Immulite®) and 0.63 (Centaur®), respectively (both p < 0.0001). In the PSA range of ≤4 ng/ml, the observed correlations were 0.75 and 0.70, respectively. For the POC test system, AUC for detection of PC was calculated with 0.745 while the standard laboratory tests showed 0.778 (Immulite®) and 0.771 (Centaur®). At best cut-off of 3.64 ng/ml, PSA analysis by the POC system showed a sensitivity of 85.7 % and a specificity of 66.7 %.

Conclusions

The POC system obtained good concordance to elaborate laboratory measurement. In a screening scenario, the system provides quick and reliable PSA measurement, especially in the PSA range up to 4 ng/ml.
Literature
1.
go back to reference Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979;17(2):159–63.PubMed Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979;17(2):159–63.PubMed
2.
go back to reference Gui-Zhong L, Libo M, Guanglin H, Jianwei W. The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis. Int Urol Nephrol. 2011;43(2):295–301.PubMedCrossRef Gui-Zhong L, Libo M, Guanglin H, Jianwei W. The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis. Int Urol Nephrol. 2011;43(2):295–301.PubMedCrossRef
3.
go back to reference Mochtar CA, Kiemeney LA, Laguna MP, van Riemsdijk MM, Barnett GS, Debruyne FM, et al. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology. 2005;65(2):300–5.PubMedCrossRef Mochtar CA, Kiemeney LA, Laguna MP, van Riemsdijk MM, Barnett GS, Debruyne FM, et al. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology. 2005;65(2):300–5.PubMedCrossRef
4.
go back to reference Stancik I, Luftenegger W, Klimpfinger M, Muller MM, Hoeltl W. Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol. 2004;46(6):760–4.PubMedCrossRef Stancik I, Luftenegger W, Klimpfinger M, Muller MM, Hoeltl W. Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur Urol. 2004;46(6):760–4.PubMedCrossRef
5.
go back to reference Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract. 2004;58(4):382–90.PubMedCrossRef Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract. 2004;58(4):382–90.PubMedCrossRef
6.
go back to reference Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology. 1999;53(3):473–80.PubMedCrossRef Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology. 1999;53(3):473–80.PubMedCrossRef
7.
go back to reference Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53(3):581–9.PubMedCrossRef Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53(3):581–9.PubMedCrossRef
8.
go back to reference Lintz K, Moynihan C, Steginga S, Norman A, Eeles R, Huddart R, et al. Prostate cancer patients’ support and psychological care needs: survey from a non-surgical oncology clinic. Psychooncology. 2003;12(8):769–83.PubMedCrossRef Lintz K, Moynihan C, Steginga S, Norman A, Eeles R, Huddart R, et al. Prostate cancer patients’ support and psychological care needs: survey from a non-surgical oncology clinic. Psychooncology. 2003;12(8):769–83.PubMedCrossRef
9.
go back to reference Brouwer N, van Pelt J. Validation and evaluation of eight commercially available point of care CRP methods. Clin Chim Acta. 2015;439:195–201.PubMedCrossRef Brouwer N, van Pelt J. Validation and evaluation of eight commercially available point of care CRP methods. Clin Chim Acta. 2015;439:195–201.PubMedCrossRef
10.
go back to reference Syal K. Point of care testing for measurement of white blood cell count and C-reactive protein levels in blood. Clin Chim Acta. 2014;437:218.PubMedCrossRef Syal K. Point of care testing for measurement of white blood cell count and C-reactive protein levels in blood. Clin Chim Acta. 2014;437:218.PubMedCrossRef
11.
go back to reference Knaebel J, Irvin BR, Xie CZ. Accuracy and clinical utility of a point-of-care HbA1c testing device. Postgrad Med. 2013;125(3):91–8.PubMedCrossRef Knaebel J, Irvin BR, Xie CZ. Accuracy and clinical utility of a point-of-care HbA1c testing device. Postgrad Med. 2013;125(3):91–8.PubMedCrossRef
12.
go back to reference Sanchez-Mora C, S Rodríguez-Oliva M, Fernández-Riejos P, Mateo J, Polo-Padillo J, Goberna R. Evaluation of two HbA1c point-of-care analyzers. Clin Chem Lab Med. 2011;49(4):653–7.PubMedCrossRef Sanchez-Mora C, S Rodríguez-Oliva M, Fernández-Riejos P, Mateo J, Polo-Padillo J, Goberna R. Evaluation of two HbA1c point-of-care analyzers. Clin Chem Lab Med. 2011;49(4):653–7.PubMedCrossRef
13.
go back to reference Karim O, Rao A, Emberton M, Cochrane D, Partridge M, Edwards P, et al. Point-of-care PSA testing: an evaluation of PSAwatch. Prostate Cancer Prostatic Dis. 2007;10(3):270–3.PubMedCrossRef Karim O, Rao A, Emberton M, Cochrane D, Partridge M, Edwards P, et al. Point-of-care PSA testing: an evaluation of PSAwatch. Prostate Cancer Prostatic Dis. 2007;10(3):270–3.PubMedCrossRef
14.
go back to reference Slev PR, La’ulu SL, Roberts WL. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol. 2008;129(6):952–8.PubMedCrossRef Slev PR, La’ulu SL, Roberts WL. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol. 2008;129(6):952–8.PubMedCrossRef
15.
go back to reference Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79.PubMedCrossRef Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79.PubMedCrossRef
16.
go back to reference Shen S, Lepor H, Yaffee R, Taneja SS. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol. 2005;173(3):777–80.PubMedCrossRef Shen S, Lepor H, Yaffee R, Taneja SS. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol. 2005;173(3):777–80.PubMedCrossRef
17.
go back to reference Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–46.PubMedCrossRef Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–46.PubMedCrossRef
18.
go back to reference Wilkinson S, Warren K, Ramsden A, Matthews A, Chodak G. Do “rapid” PSA assays reduce anxiety and stress of prostate cancer patients undergoing regular review? A prospective evaluation. Urology. 2008;71(4):567–72.PubMedCrossRef Wilkinson S, Warren K, Ramsden A, Matthews A, Chodak G. Do “rapid” PSA assays reduce anxiety and stress of prostate cancer patients undergoing regular review? A prospective evaluation. Urology. 2008;71(4):567–72.PubMedCrossRef
19.
go back to reference Miano R, Mele GO, Germani S, Bove P, Sansalone S, Pugliese PF, et al. Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen test. Prostate Cancer Prostatic Dis. 2005;8(3):219–23.PubMedCrossRef Miano R, Mele GO, Germani S, Bove P, Sansalone S, Pugliese PF, et al. Evaluation of a new, rapid, qualitative, one-step PSA Test for prostate cancer screening: the PSA RapidScreen test. Prostate Cancer Prostatic Dis. 2005;8(3):219–23.PubMedCrossRef
20.
go back to reference Oh SW, Kim YM, Kim HJ, Kim SJ, Cho JS, Choi EY. Point-of-care fluorescence immunoassay for prostate specific antigen. Clin Chim Acta. 2009;406(1-2):18–22.PubMedCrossRef Oh SW, Kim YM, Kim HJ, Kim SJ, Cho JS, Choi EY. Point-of-care fluorescence immunoassay for prostate specific antigen. Clin Chim Acta. 2009;406(1-2):18–22.PubMedCrossRef
21.
go back to reference Oberpenning F, Hetzel S, Weining C, Brandt B, De Angelis G, Heinecke A, et al. Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer? Eur Urol. 2003;43(5):478–84.PubMedCrossRef Oberpenning F, Hetzel S, Weining C, Brandt B, De Angelis G, Heinecke A, et al. Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer? Eur Urol. 2003;43(5):478–84.PubMedCrossRef
Metadata
Title
Assessment of a new point-of-care system for detection of prostate specific antigen
Authors
Steffen Rausch
Joerg Hennenlotter
Josef Wiesenreiter
Andrea Hohneder
Julian Heinkele
Christian Schwentner
Arnulf Stenzl
Tilman Todenhöfer
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2016
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-016-0119-9

Other articles of this Issue 1/2016

BMC Urology 1/2016 Go to the issue